Director, Patient Marketing

USA (Remote)

$200K/yr – $220K/yrDirector/Executive8+ years expFull time

Posted 2 months ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Own end-to-end patient marketing and advocacy programs that connect education, access, and support across HCP, Market Access, and Patient Services.

  • Align unbranded disease education and patient campaigns with pre-launch goals and patient outcomes.
  • Shape cross-functional activation with research, advocacy, and social listening to drive measurable PSP enrollment and persistence.

Job Description

Responsibilities

  • Own the patient and caregiver journey, identifying the moments that matter across education, identification, treatment consideration, onboarding, access, initiation, adherence, and persistence.
  • Partner with market research to design and interpret patient and caregiver research, social listening, and advocacy input. Translate findings into clear strategic recommendations, messaging direction, and program priorities.
  • Ensure patient strategy is connected to HCP, Market Access, Patient Services, and advocacy plans, with shared accountability for identification, conversion, persistence, and PSP enrollment outcomes.
  • Lead the unbranded disease education and condition awareness strategy in the pre-launch window, building patient understanding of uncontrolled and resistant hypertension and the role of aldosterone.
  • Partner with HCP Marketing on shared moments where patient and HCP voices intersect, including congresses, advocacy events, and co-developed content.
  • Lead branded and unbranded patient campaigns end to end, from brief through execution across disease education, awareness, and support. Set strategic direction, define success, and oversee content development across print, digital, social, video, webinar, and educational formats in partnership with the AOR, media agency, production partners, and Omnichannel & Digital Marketing.
  • Partner with Omnichannel & Digital Marketing lead to connect patient activation tactics to the broader campaign architecture.
  • Partner with Patient Services and Market Access on PSP design and the broader patient support experience, including enrollment, hub interactions, copay, education materials, and adherence touchpoints, so the program reflects patient needs and reinforces onboarding, access navigation, and persistence.
  • Manage patient facing materials through Veeva PromoMats and the PRC process.
  • Develop and lead patient advocacy, ambassador, influencer, and community engagement strategies, including objectives, audience definition, content guardrails, compliance considerations, and performance measures.

Requirements

  • Bachelor's degree required; MBA or advanced degree preferred.
  • 8+ years of pharmaceutical or biotech experience with significant patient marketing strategy and execution responsibility.
  • Launch experience strongly preferred.
  • Experience leading AOR and specialty agency partners across creative, research, advocacy, and social or influencer programs.
  • Cardiovascular or chronic disease experience preferred.
  • Travel: Up to 20%, occasionally international.

Preferred

Mineralys Therapeutics logo

Mineralys Therapeutics

5.0 Glassdoor

At Mineralys Therapeutics we aim to redefine hypertension diagnosis, management and treatment. We are driven to break the “trial and failure” approach to hypertension management and bring a personalized approach to the management of hypertension.

Founded in 2020
Wayne, Pennsylvania, USA
84 employees (3 in marketing)
0% recommend to a friend

Traffic Signals

Monthly Visitors
9.8K
Traffic Source Mix
Search
35.6%
Direct
44.3%
Referral
5.7%
Social
12.7%
Paid
1.5%

Headcount Trend

Current headcount: ~84

Marketing Team

Marketing Team Size
3 (4% of company)
Marketing Roles Posted (Last 30 Days)
3

Funding

Total Funding
$740.5M
Last Raise
$287.5M
Post IPO Equity, 7 months ago

Funding History

  • Sep 2025
    Post IPO Equity • $287.5M
  • Mar 2025
    Post IPO Equity • $175M
  • Feb 2024
    Post IPO Equity • $120M

Recent News